Acetylsalicylic acid + Clopidogrel + Rivaroxaban
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aortic Valve Stenosis
Conditions
Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Trial Timeline
May 1, 2016 → Mar 6, 2019
NCT ID
NCT02833948About Acetylsalicylic acid + Clopidogrel + Rivaroxaban
Acetylsalicylic acid + Clopidogrel + Rivaroxaban is a phase 3 stage product being developed by Bayer for Aortic Valve Stenosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02833948. Target conditions include Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02833948 | Phase 3 | Completed |
Competing Products
20 competing products in Aortic Valve Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 77 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 85 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| candesartan + placebo | AstraZeneca | Phase 3 | 77 |
| Sugammadex | Merck | Approved | 85 |
| bisoprolol + placebo | Merck | Approved | 85 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 65 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 52 |
| fluvastatin | Novartis | Phase 2 | 52 |
| ACZ885 + Placebo | Novartis | Phase 2 | 52 |
| Evolocumab + Placebo | Amgen | Phase 1 | 32 |
| atorvastatin (Lipitor) | Pfizer | Approved | 84 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 32 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 51 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 51 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 74 |
| Desflurane | Baxter | Approved | 82 |